Ratings Roche Holding AG Swiss Exchange

Equities

RO

CH0012032113

Market Closed - Swiss Exchange Other stock markets 11:30:41 2024-05-31 am EDT			5-day change	1st Jan Change
252.8 ^CHF	+1.04%		+0.32%	-3.29%

May. 31	ROCHE HOLDINGS AG : Gets a Neutral rating from UBS	ZD
May. 31	Transcript : Roche Holding AG - Shareholder/Analyst Call

Summary

Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
This company will be of major interest to investors in search of a high dividend stock.
Considering the small differences between the analysts' various estimates, the group's business visibility is good.

Weaknesses

With an enterprise value anticipated at 3.28 times the sales for the current fiscal year, the company turns out to be overvalued.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
ROCHE HOLDING AG	-3.29%	206B	-
ELI LILLY AND COMPANY	+40.73%	739B	C+
NOVO NORDISK A/S	+32.83%	598B	B
JOHNSON & JOHNSON	-6.30%	353B	C+
MERCK & CO., INC.	+15.15%	318B	B-
ABBVIE INC.	+4.05%	285B	C+
ASTRAZENECA PLC	+15.00%	240B	B+
AMGEN INC.	+6.17%	164B	C+
PFIZER, INC.	-0.45%	162B	C+
SANOFI	-.--%	122B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes